Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML.

Autor:	García-Dabrio MC; From the Departments of Hematology and Laboratory and., Hoyos M; Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona, Spain;, Brunet S; Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona, Spain;, Tormo M; Department of Hematology, Hospital Clínic, Valencia, Spain;, Ribera JM; Department of Hematology, Hospital ICO Germans Trias i Pujol, Badalona, Spain;, Esteve J; Department of Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain;, Gallardo D; Department of Hematology, Hospital ICO Hospital Josep Trueta, Girona, Spain;, Duarte RF; Department of Hematology, Hospital ICO Duran i Reynalds, L'Hospitalet, Barcelona, Spain;, de Llano MP; Department of Hematology, Hospital Virgen de la Victoria, Malaga, Spain;, Bargay J; Department of Hematology, Hospital Sont Llatzer, Palma de Mallorca, Spain;, Martí-Tutusaus JM; Department of Hematology, Hospital de la Mutua de Terrassa, Terrassa, Spain;, Heras I; Department of Hematology, Hospital Virgen de la Arrixaca, Murcia, Spain;, Garcia A; Department of Hematology, Hospital Arnau de Vilanova, Lleida, Spain;, Salamero O; Department of Hematology, Hospital de la Vall d' Hebrón, Barcelona, Spain; and., Aventin A; From the Departments of Hematology and Laboratory and., Lecrevisse Q; Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (USAL) and Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain, on behalf of the Spanish CETLAM Group., Orfao A; Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (USAL) and Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain, on behalf of the Spanish CETLAM Group., Sierra J; Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona, Spain;, Nomdedéu JF; From the Departments of Hematology and Laboratory and jnomdedeu@santpau.cat.
Jazyk:	angličtina
Zdroj:	American journal of clinical pathology [Am J Clin Pathol] 2015 Sep; Vol. 144 (3), pp. 484-92.
DOI:	10.1309/AJCPRL6XSVFMLH9V
Abstrakt:	Objectives: The prognostic impact of immunophenotypic markers in acute myeloid leukemia (AML) is controversial. Methods: We retrospectively analyzed the value of CD34, CD117, CD7, and CD123 expression in a consecutive series of 592 adult patients with de novo AML. Results: CD34+ measured as a percentage (≥2.88%) and CD34 mean fluorescence intensity (MFI) (≥146.79, arbitrary units [AU]) expression had a prognostic impact in terms of overall survival (OS; P = .005, P = .003), leukemia-free survival (LFS; P = .011, P < .001), and cumulative incidence of relapse (CIR; P = .014, P =. 001). The percentage of CD117+ cells (61.29%) was associated with shorter LFS (P =. 043), and CD117 MFI (≥284.01 AU) was associated with a shorter OS (P =. 033) and LFS (P =. 028). In the multivariate analysis, high CD34 MFI retained the independent value as predictor of LFS and CIR (P =. 012; hazard ratio [HR], 1.59; 95% confidence interval [CI], 1.11-2.28 and P =. 045; HR, 1.58; 95% CI, 1.01-2.46). Conclusions: CD34 positivity threshold with prognostic relevance is low (3% positive cells). Immunophenotypic findings in AML probably could only be fully exploited after a complex analysis that takes into account unconventional thresholds and the MFI. (Copyright© by the American Society for Clinical Pathology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu